Dolby Laboratories, Inc.
NYSE:DLBInformation Technology Services
-$0.10 today
- Market cap
- $5.32B
- Beta
- 0.80
- P/E (TTM)
- 20.0
- EPS (TTM)
- $2.56
- Dividend yield
- 2.76%
Volume 2.61M
Average 0.73M
DLB Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Dolby Laboratories, Inc.NYSE: DLB
Accounts Receivables · Q3 FY2026 · quarter ended Jun 2026
Accounts receivables growth accelerates
Q3 FY2026 accounts receivables of $137.6M rose 230.7% year over year, ahead of the -6088.4% change in trailing-twelve-month accounts receivables.
Context
- Accounts receivables amounted to 1.1% of revenue in FY2026, up 0.9 pp from a year earlier.
- Accounts receivables increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +230.7% holds above the trailing-twelve-month pace of -6088.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2026
- (15.28M) USD
- Year-over-year change
- -757.0%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2026 | 2026-09-25 | (15.28M) | -757.0% |
| FY2025 | 2025-09-26 | (1.78M) | +95.3% |
| FY2024 | 2024-09-27 | (37.67M) | -178.3% |
| FY2023 | 2023-09-29 | 48.13M | +700.5% |
| FY2022 | 2022-09-30 | (8.01M) | — |
Accounts Receivables vs competitors
How DLB compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -6088.4% is the lowest of 10, against a peer median of +100.0%.
- Accounts receivables amounts to 2.7% of revenue for DLB, versus a peer median of 3.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
INGMIngram Micro Holding Corporation | LTM Jun 2026 | $1.85B USD | +54.2% | +23.3% | 3.3% |
| LTM Sep 2026 | $369.75M USD | +356.1% | -26.7% | 6.9% | |
| LTM Jun 2026 | $174M USD | -201.2% | — | 0.7% | |
| LTM Jun 2026 | $90.98M USD | +566.1% | -19.2% | 4.1% | |
| LTM Sep 2026 | $53.78M USD | — | — | 4.1% | |
| LTM Jun 2026 | $39.89M USD | +66.2% | — | 1.9% | |
| LTM Jun 2026 | $39.1M USD | +162.9% | +6.8% | 0.8% | |
| LTM Jun 2026 | $37.07M USD | -6088.4% | — | 2.7% | |
| LTM Jun 2026 | $31.47M USD | -665.5% | +30.5% | 2.6% | |
| LTM Jun 2026 | $20.84M USD | +192.0% | — | 3.4% | |
| LTM Jun 2026 | CN¥0 CNY | +100.0% | — | 0.0% | |
| Peer median (excluding DLB) | — | +100.0% | +6.8% | 3.0% | |
Competitors are the stored peer set for DLB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 | FY2026 Sep 2026 |
|---|---|---|---|---|---|
| Net Income | 183.9M | 201.64M | 264.32M | 256.49M | 257.74M |
| Depreciation & Amortization | 103.61M | 95.51M | 87.33M | 98.6M | 105.27M |
| Deferred Income Tax | (29.47M) | (18.34M) | (21.61M) | 4.99M | 1.18M |
| Stock-Based Compensation | 114.93M | 118.49M | 119.83M | 128.51M | 133.29M |
| Change in Working Capital | (56.25M) | (47.08M) | (118.71M) | (17.01M) | (94.48M) |
| Accounts Receivables | (8.01M) | 48.13M | (37.67M) | (1.78M) | (15.28M) |
| Inventory | (11.76M) | (13.23M) | (2.65M) | 8.02M | 10.2M |
| Accounts Payables | 0 | 0 | 0 | 22.85M | 40.29M |
| Other Working Capital | (36.48M) | (81.98M) | (78.38M) | (46.1M) | (129.68M) |
| Other Non-Cash Items | 1.86M | 16.86M | (3.89M) | 619K | (3.45M) |
| Operating Cash Flow | 318.58M | 367.08M | 327.25M | 472.2M | 399.55M |
| Capital Expenditures | (59.46M) | (30.34M) | (30.01M) | (41.94M) | (39.63M) |
| Acquisitions (Net) | (38.17M) | 25.7M | (487.88M) | (1.36M) | 0 |
| Purchases of Investments | (316.31M) | (172.96M) | (160.2M) | (75K) | 0 |
| Sales of Investments | 118.01M | 231.8M | 391.79M | 15.91M | 0 |
| Other Investing Activities | (11.53M) | 0 | 0 | 11.29M | (44.55M) |
| Investing Cash Flow | (295.94M) | 54.21M | (286.29M) | (10.59M) | (84.18M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 57.85M | 47.78M | 40.2M | 43.7M | 27.27M |
| Common Stock Repurchased | (566.9M) | (180.42M) | (199.08M) | (162.23M) | (265M) |
| Dividends Paid | (100.07M) | (103.41M) | (114.58M) | (126.6M) | (136.32M) |
| Other Financing Activities | (1.44M) | (766K) | (14.36M) | (2.11M) | (36.84M) |
| Financing Cash Flow | (610.56M) | (236.81M) | (287.81M) | (247.24M) | (410.89M) |
| Effect of Forex Changes | (16.74M) | 5.12M | 6.64M | 1.24M | 52K |
| Net Change in Cash | (604.66M) | 189.6M | (240.21M) | 215.61M | (95.48M) |
| Free Cash Flow | 259.12M | 336.74M | 297.25M | 430.26M | 359.91M |
Dolby Laboratories, Inc.
NYSE:DLB
Intrinsic Alpha fair value
Locked
Current Price
$56.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.